PROM1 and cancer: Besides confirming the higher number of ECVs in metastatic and locally advanced nonhematological cancer patients, these authors observed a higher concentration of circulating ECVs originating from endothelial (CD31+) and tumor cancer stem cells (CD133+ CD326-).